Bills › 88th General Assembly

Relating to continuity of care and nonmedical switching by health carriers, health benefit plans, and utilization review organizations, and including applicability provisions

Topics:Health care

Same legislation: HF 204, SF 489

Where it is now

  1. Done: IntroducedFebruary 4, 2019
  2. Done: SubcommitteeFebruary 20, 2019
  3. Done: Senate committeeMarch 6, 2019
  4. Skipped: Passes the SenateContinued as SF 489
  5. Next: House committee
  6. Next: Passes the House
  7. Next: To the Governor
  8. Next: Signed into law

Became SF 489 → Its progress continues under the new number. Go to SF 489 What’s a funnel?

What’s in it

This bill relates to the continuity of care for a covered person and nonmedical switching by health carriers, health benefit plans, and utilization review organizations. The bill defines “nonmedical switching” as a health benefit plan’s restrictive changes to the health benefit plan’s formulary after the current plan year has begun or during the open enrollment period for the upcoming plan year, causing a covered person who is medically stable on the covered person’s current prescribed drug as determined by the prescribing health care professional, to switch to a less costly alternate prescription drug.

Read the full explanation

The bill provides that during a covered person’s eligibility under a health benefit plan, inclusive of any open enrollment period, a health plan carrier, health benefit plan, or utilization review organization shall not limit or exclude coverage of a prescription drug for the covered person if the covered person is medically stable on the drug as determined by the prescribing health care professional, the drug was previously approved by the health carrier for coverage for the person, and the person’s prescribing health care professional has prescribed the drug for the covered person’s medical condition within the previous six months. The bill includes, as prohibited limitations or exclusions, reducing the maximum coverage of prescription drug benefits, increasing cost sharing for a covered drug, moving a drug to a more restrictive tier, and removing a drug from a formulary. A prescription drug may, however, be removed from a formulary if the United States food and drug administration issues a statement regarding the clinical safety of the drug, or the manufacturer of the drug notifies the United States food and drug administration of a manufacturing discontinuance or potential discontinuance of the drug as required by section 506c of the Federal Food, Drug, and Cosmetic Act. The bill requires a covered person and prescribing health care professional to have access to a process to request a coverage exemption determination. The bill defines “coverage exemption determination” as a determination made by a health carrier, health benefit plan, or utilization review organization whether to cover a prescription drug that is otherwise excluded from coverage. A coverage exemption determination request must be approved or denied by the health carrier, health benefit plan, or utilization review organization within hours, or within hours if exigent circumstances exist. If a determination is not received within the applicable time period the coverage exemption is deemed granted. The bill requires a coverage exemption to be expeditiously granted for a health benefit plan discontinued for the next plan year if a covered person enrolls in a comparable plan offered by the same health carrier, and in comparison to the discontinued health benefit plan, the new health benefit plan limits or reduces the maximum coverage for a prescription drug, increases cost sharing for the prescription drug, moves the prescription drug to a more restrictive tier, or excludes the prescription drug from the formulary. If a coverage exemption is granted, the bill requires the authorization of coverage that is no more restrictive than that offered in a discontinued health benefit plan, or than that offered prior to implementation of restrictive changes to the health benefit plan’s formulary after the current plan year began. If a determination is made to deny a request for a coverage exemption, the reason for denial and the procedure to appeal the denial must be provided to the requestor. Any determination to deny a coverage exemption may be appealed to the health carrier, health benefit plan, or utilization review organization. A determination to uphold or reverse denial of a coverage exemption must be made within hours of receipt of an appeal, or within hours if exigent circumstances exist. If a determination is not made within the applicable time period, the denial is deemed reversed and the coverage exemption is deemed approved. If a determination to deny a coverage exemption is upheld on appeal, the reason for upholding the denial and the procedure to request external review of the denial pursuant to Code chapter 514J must be provided to the individual who filed the appeal. Any denial of a request for a coverage exemption that is upheld on appeal is considered a final adverse determination for purposes of Code chapter 514J and is eligible for a request for external review by a covered person or the covered person’s authorized representative pursuant to Code chapter 514J. The bill shall not be construed to prevent a health care professional from prescribing another drug covered by the health carrier that the health care professional deems medically necessary for the covered person. The bill shall not be construed to prevent a health carrier from adding a drug to its formulary or removing a drug from its formulary if the drug manufacturer removes the drug for sale in the United States.32. The bill allows the commissioner to take any necessary enforcement action under the commissioner’s authority to enforce compliance with the bill. The bill is applicable to health benefit plans that are delivered, issued for delivery, continued, or renewed in this state on or after January 1, 2020.

Full bill text1

Senate subcommittee

Named February 20, 2019. It hasn’t reported yet.

Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part

Fiscal note

AI summary Senate File 489 requires health plans to provide continuity of care for people with epilepsy by prohibiting nonmedical switching of prescribed drugs. The Insurance Division would face approximately $41,100 in administrative costs to monitor these changes and perform reviews. Additionally, the State of Iowa employee group plan is estimated to see an annual increase in drug spending for epilepsy treatments between $21,000 and $115,000.2

Read the fiscal note

Description

Senate File 489 requires continuity of care for covered persons with epilepsy; prohibits nonmedical switching by health carriers, health benefit plans, and utilization review organizations; and includes applicability provisions. The Bill provides exceptions for nonmedical switching if the U.S. Food and Drug Administration (FDA) issues a statement regarding the clinical safety of the drug, or if the manufacturer notifies the FDA of a discontinuance or planned discontinuance of the drug.

Background

Drug costs to the State of Iowa for medications related to the treatment of epilepsy were approximately $1.0 million in FY 2018.

Nonmedical switching is the practice of switching a covered person’s prescribed drug to a less costly alternative while the person has been determined to be medically stable while on the drug, without medical reasons given by the person’s prescribing health care professional.

Assumptions

Enforcement

  • Monitoring nonmedical switching would create an estimated five external reviews per week averaging three hours each for the Insurance Division of the Department of Commerce.
  • External reviews would require an Insurance Program Specialist at a rate of $49.31 per hour.
  • Actively monitoring carriers’ prescription drug benefits or changes would require an estimated 50 additional hours of Insurance Division staff time per year at a rate of $52.89 per hour.

State of Iowa Employee Group Plan

  • Formulary management currently results in cost of care savings between 2.0% and 11.0%.

Fiscal Impact

Total administrative costs associated with SF489 that would be realized by the Insurance Division to monitor and perform external reviews would be approximately $41,100. The estimated annual increase in drug spending for the treatment of epilepsy for the State of Iowa employee group plan is between $21,000 and $115,000.

Sources

  • Iowa Department of Commerce, Insurance Division
  • Wellmark Blue Cross Blue Shield
  • Department of Administrative Services

Reading a fiscal note3

Iowa Code it changes

Creates§514F.8

How the Code works4

Lobbying

13 for · 7 against · 23 undecided · Who →

Family tree

Earlier and later bills are matched by wording or an identical title.

Similar bills

  • HF 2089 Relating to continuity of care and nonmedical switching by health carriers, health benefit…
    88th General Assembly · Approved by committee
    Nearly identical
  • SF 178 Relating to continuity of care and nonmedical switching by health carriers, health benefit…
    89th General Assembly · Subcommittee recommends passage
    Nearly identical
  • SF 2016 Relating to continuity of care and nonmedical switching by health carriers, health benefit…
    89th General Assembly · In committee
    Nearly identical
  • HF 372 Relating to continuity of care and nonmedical switching by health carriers, health benefit…
    89th General Assembly · Renumbered as HF 656
    Nearly identical
  • HF 96 Relating to continuity of care and nonmedical switching by health carriers, health benefit…
    90th General Assembly · Renumbered as HF 626
    Very similar

Matched by wording or an identical title.